


COVID-19 Vaccination Schedule

for Moderately to Severely Immunocompromised Patients

Includes blood cancer patients and most survivors

If you are moderately to severely immunocompromised, you are at increased risk of severe COVID-19 illness and death. Additionally, your immune response to vaccination may not be as strong as in people who are not immunocompromised, so additional vaccine doses are needed. Even after receiving all recommended vaccines, LLS encourages blood cancer patients to take additional precautions, like wearing a mask and social distancing.

The charts below include information about the number and timing of COVID-19 vaccine doses for everyone 6 months of age and older. Individuals should consult with their healthcare provider about any changes to the number or timing of their doses due to their cancer diagnosis or its treatment, or receipt of monoclonal antibodies (you can find more information in our COVID FAQs).



The mission of The Leukemia & Lymphoma Society (LLS) is to cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. Find out more at www.LLS.org.



primary series.

Pfizer-BioNTech (Comirnaty) Ages 6 months - 4 years Ages **5 – 11 years** Ages 12 years and older **Primary Dose 1 Primary Dose 1 Primary Dose 1** Wait 3 weeks Wait 3 weeks Wait 3 weeks **Primary Dose 2 Primary Dose 2 Primary Dose 2** Additional primary dose for Additional primary dose for immunocompromised patients immunocompromised patients Wait at least 8 weeks Wait at least Wait at least 4 weeks 4 weeks (2 months) **Primary Dose 3 Primary Dose 3 Primary Dose 3** Wait at least Wait at least 8 weeks 8 weeks (2 months) (2 months) **NOTE ABOUT BIVALENT BOOSTER:** The first two primary doses should be with the monovalent vaccine. The **Bivalent Bivalent** third primary dose should **Booster Booster** be with the bivalent vaccine. Children in this age group who received three monovalent vaccines for their primary NOTE: Regardless of health or immune status, everyone who is eligible series should receive a bivalent should receive only one COVID-19 bivalent booster dose. Repeat dosing booster dose at least two with bivalent boosters is not recommended at this time. LLS monitors new months after completing their scientific information and public health recommendations closely and will

The mission of The Leukemia & Lymphoma Society (LLS) is to cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. Find out more at www.LLS.org.

update this information as needed.

COVID-19 Vaccination Schedule for Moderately to Severely Immunocompromised Patients

Novavax

Ages 12 years and older



NOTE: Regardless of health or immune status, everyone who is eligible should receive only one COVID-19 bivalent booster dose. Repeat dosing with bivalent boosters is not recommended at this time. LLS monitors new scientific information and public health recommendations closely and will update this information as needed.



Get vaccinated as recommended even if you had COVID-19



Keep practicing social distancing and masking



Talk to your healthcare team if unsure of your risk